MARKET

VCYT

VCYT

Veracyte
NASDAQ
18.63
+1.54
+9.01%
Closed 16:15 10/04 EDT
OPEN
17.61
PREV CLOSE
17.09
HIGH
18.65
LOW
17.57
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
54.13
52 WEEK LOW
14.85
MARKET CAP
1.33B
P/E (TTM)
-27.1179
1D
5D
1M
3M
1Y
5Y
New Data Published In Journal of the National Cancer Institute Demonstrate Veracyte's Decipher Prostate Genomic Classifier May Improve Identification Of Aggressive Prostate Cancer In African American Men
Veracyte, Inc. (NASDAQ:VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company's Decipher Prostate Genomic Classifier may help identify African
Benzinga · 09/22 12:56
Veracyte's Decipher Prostate Genomic Classifier May Help Identify Aggressiveness of Prostate Cancer in African American Men
Veracyte's Decipher Prostate Genomic Classifier May Help Identify Aggressiveness of Prostate Cancer in African American Men
MT Newswires · 09/22 11:50
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
SOUTH SAN FRANCISCO, Calif., September 13, 2022--Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
Business Wire · 09/13 12:30
BRIEF-New Data Presented At ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions In Men With Advanced Prostate Cancer
BRIEF-New Data Presented At ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions In Men With Advanced Prostate Cancer
Reuters · 09/11 07:04
New Data Suggest Veracyte's Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
Veracyte, Inc. (NASDAQ:VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary
Benzinga · 09/07 20:55
Veracyte to Present Data Supporting Its Genomic Diagnostic Tool at Industry Conference
Veracyte to Present Data Supporting Its Genomic Diagnostic Tool at Industry Conference
MT Newswires · 09/07 17:32
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., September 01, 2022--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 20th Annual ...
Business Wire · 09/01 21:00
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
SOUTH SAN FRANCISCO, Calif., August 31, 2022--Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medi...
Business Wire · 08/31 11:00
More
About VCYT
Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Webull offers kinds of Veracyte Inc stock information, including NASDAQ:VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.